- Conditions
- COVID-19
- Interventions
- Pamrevlumab, Placebo
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Greensboro, North Carolina • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 233
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dry Eye Disease
- Interventions
- Cenegermin, Vehicle
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Glendale, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
- Conditions
- EGFR Inhibitor-associated Rash
- Interventions
- Menadione Topical Lotion
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- Vallejo, California • Chicago, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Migraine
- Interventions
- Erenumab, Placebo, PACAP-38 Challenge Agent
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Presbyopia
- Interventions
- CSF-1, Vehicle
- Drug
- Lead sponsor
- Orasis Pharmaceuticals Ltd.
- Industry
- Eligibility
- 45 Years to 64 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 18
- States / cities
- Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 15 more
- Conditions
- Hypochondroplasia
- Interventions
- infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more
- Conditions
- Ovarian Neoplasms
- Interventions
- AMG 479, AMG 479 Placebo
- Drug
- Lead sponsor
- Translational Research in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 23
- States / cities
- Alhambra, California • Burbank, California • Fullerton, California + 17 more
- Conditions
- Presbyopia
- Interventions
- CSF-1, CSF-1 Component #1, CSF-1 Component #2
- Drug
- Lead sponsor
- Orasis Pharmaceuticals Ltd.
- Industry
- Eligibility
- 45 Years to 64 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 7
- States / cities
- Newport Beach, California • Littleton, Colorado • Andover, Massachusetts + 4 more
- Conditions
- Alveolar Bone Loss, Periodontal Diseases
- Interventions
- beta-tricalcium phosphate alone, GFeBGS 0.1%, GFeBGS 0.3%, GFeBGS 0.4%
- Device
- Lead sponsor
- Sunstar Americas
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Fullerton, California • Aurora, Colorado + 3 more
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
- Interventions
- Erythropoietin, Sham Comparator
- Drug · Other
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 24 Hours to 96 Days
- Enrollment
- 318 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2000
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
- Conditions
- Anemia, Chronic Kidney Disease (CKD)
- Interventions
- HX575 epoetin alfa, US-licensed epoetin alfa
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 52
- States / cities
- Tempe, Arizona • Azusa, California • Bakersfield, California + 42 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- JK07, Matching Placebo
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Stanford, California • Boston, Massachusetts • Rochester, Minnesota + 4 more
- Conditions
- Non Squamous, Non-small-cell Lung Cancer
- Interventions
- Tivantinib, Placebo, Erlotinib
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,048 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 111
- States / cities
- Tucson, Arizona • Los Angeles, California • Oxnard, California + 85 more
- Conditions
- Covid19
- Interventions
- CAP-1002, Placebo
- Biological
- Lead sponsor
- Capricor Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Sacramento, California • Detroit, Michigan + 1 more
- Conditions
- Ovarian Neoplasms, Ascites
- Interventions
- aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Interventions
- LY2382770, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Inglewood, California • Los Angeles, California + 25 more
- Conditions
- Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
- Interventions
- G-CSF plus Plerixafor
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
- Interventions
- AL58805, AL3818, Temozolomide (TMZ), CCNU
- Drug
- Lead sponsor
- Advenchen Pharmaceuticals, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ulcer, Leg Ulcer, Varicose Ulcer, Pathologic Processes, Skin Ulcer, Skin Diseases, Vascular Diseases, Cardiovascular Diseases
- Interventions
- Placebo, VF001-DP LD, VF001-DP HD
- Biological
- Lead sponsor
- Factor Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 17
- States / cities
- Carlsbad, California • Fresno, California • Laguna Hills, California + 10 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar
- Drug
- Lead sponsor
- Epitopoietic Research Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 3
- States / cities
- Orange, California • Boston, Massachusetts
- Conditions
- Mastectomy, Gender Affirmation Surgery, Nipple Sparing Mastectomy, Prophylactic Mastectomy, Benign Breast Condition
- Interventions
- AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft, Control Device
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Multiple System Atrophy
- Interventions
- AAV2-GDNF gene therapy, Sham (Placebo) Surgery
- Biological · Procedure
- Lead sponsor
- Brain Neurotherapy Bio, Inc.
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
- Conditions
- Detrusor Overactivity, Overactive Bladder
- Interventions
- Placebo, solifenacin
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 547 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- New York, New York • West Reading, Pennsylvania